Exelixis: Other Events
The following excerpt is from the company's SEC filing
By letter dated November 26, 2013, Exelixis, Inc. (Exelixis) notified Genentech, Exelixis collaborator and a member of the
Roche Group, of Exelixis exercise of its U.S. co-promotion option under the parties worldwide co-development agreement for the MEK inhibitor cobimetinib (GDC-0973/XL518). Exelixis will provide up to 25% of the total sales force for
cobimetinib in the United States, if commercialized, and will call on customers and otherwise engage in promotional activities using that sales force, consistent with the terms of the co-development agreement and a co-promotion agreement to be
entered into by the parties.
The statements in this Current Report on Form 8-K regarding Exelixis activities in connection with the potential commercialization of
cobimetinib (GDC-0973/XL518) and the entrance into the referenced co-promotion agreement are forward-looking statements. These forward-looking statements are based upon Exelixis current plans, assumptions, beliefs and expectations.
Forward-looking statements involve risks and uncertainties. Exelixis actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which
include, without limitation: risks related to the potential failure of cobimetinib to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of cobimetinib;
Exelixis dependence on its relationship with Roche and Genentech and Exelixis ability to maintain its rights under the collaboration; the uncertainty of regulatory approval processes; market competition; and changes in economic and
business conditions. These and other risk factors are discussed under Risk Factors and elsewhere in Exelixis quarterly report on Form 10-Q for the three months ended September 27, 2013, filed with the Securities and Exchange
Commission on October 30, 2013, and Exelixis other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Exelixis expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Exelixis
makes a similar move, sign up!